The Country

From the Left · Read · November 10, 2026

Nov 9 · The FDA orders a new warning on all GLP-1 drugs, including Ozempic and Wegovy, for a rare eye condition that can cause vision loss

CBS News: CBS quotes a co-author of the 2024 study and both drugmakers; the FDA puts the rate near 6 in 100,000.

Grade A (97/100). Article: CBS News on the FDA's new GLP-1 vision warning

Lehrer score 97/100 (starts at 85; +4 named, on-record sources (2+): Dr. Joseph Rizzo, Novo Nordisk and Eli Lilly quoted by name; +4 other side quoted or given its response: Novo Nordisk "continues to believe the data do not establish a cause-and-effect relationship"; +2 key numbers sourced: "roughly 6 of every 100,000 patients who took a GLP-1 for at least one year," the FDA said; +2 context: background or what came before: NAION "affects somewhere between 2 to 10 of every 100,000 adults over age 50, according to the American Academy of Ophthalmology"). Fixed scale: 90+ A, 80s B, 70s C, 60s D, under 60 F → A.

Splits: Article: CBS News on the FDA's new GLP-1 vision warning

Read at CBS News

Same story: CNBC, New York Post

More graded coverage

How the grades work

Dispute this grade

Disagree with our approach or a rating? Have other feedback?

Tell us what you think we got wrong, or anything else. We read every message.

Become a Founding Member. Founding members get pundit scorecards free forever.

We store your email (and your name, if you give it) only to contact you about The Country. We never sell it. To be removed, unsubscribe from any email or write to [email protected].

Follow us:
About Watch Archive Join Contact Privacy Terms RSS